19:57:03 Europe / Stockholm

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

2024-11-07 Kvartalsrapport 2024-Q3
2024-08-15 Kvartalsrapport 2024-Q2
2024-05-28 Kvartalsrapport 2024-Q1
2024-05-08 X-dag ordinarie utdelning QLIFE 0.00 SEK
2024-05-07 Årsstämma 2024
2024-02-08 Bokslutskommuniké 2023
2024-01-16 Extra Bolagsstämma 2023
2023-11-13 Kvartalsrapport 2023-Q3
2023-08-17 Kvartalsrapport 2023-Q2
2023-05-26 Kvartalsrapport 2023-Q1
2023-05-05 X-dag ordinarie utdelning QLIFE 0.00 SEK
2023-05-04 Årsstämma 2023
2023-03-24 Extra Bolagsstämma 2022
2023-02-16 Bokslutskommuniké 2022
2022-11-25 Kvartalsrapport 2022-Q3
2022-08-29 Kvartalsrapport 2022-Q2
2022-05-06 X-dag ordinarie utdelning QLIFE 0.00 SEK
2022-05-05 Kvartalsrapport 2022-Q1
2022-05-05 Årsstämma 2022
2022-02-17 Bokslutskommuniké 2021
2021-11-08 Kvartalsrapport 2021-Q3
2021-08-16 Kvartalsrapport 2021-Q2
2021-05-06 X-dag ordinarie utdelning QLIFE 0.00 SEK
2021-05-05 Årsstämma 2021
2021-05-05 Kvartalsrapport 2021-Q1
2021-02-18 Bokslutskommuniké 2020
2020-11-19 Extra Bolagsstämma 2020
2020-11-18 Kvartalsrapport 2020-Q3
2020-08-18 Kvartalsrapport 2020-Q2
2020-05-22 X-dag ordinarie utdelning QLIFE 0.00 SEK
2020-05-20 Årsstämma 2020
2020-05-20 Kvartalsrapport 2020-Q1

Beskrivning

LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriMedicinteknik
Qlife Holding är verksamt inom medicinteknik. Bolaget är specialiserat inom forskning och utveckling av IVD-enheter. Enheterna används som biomarkörstester i blod och används som komplement till övriga tester inom vården. Samarbete utförs även med övriga aktörer på marknaden. Störst verksamhet återfinns inom den nordiska marknaden, med huvudkontoret i Helsingborg.
2022-06-27 15:44:40

Qlife announces today that the company has received a milestone payment of 1.23 M USD within the framework of its agreement with FIND, the global alliance for diagnostics. The payment is made in connection with Qlife achieving key milestones in the development of a new two-in-one test for influenza and SARS-CoV-2 virus.

In December 2021, Qlife signed an agreement with FIND for $ 3.45 million for a 12-month project with the goal of developing a new and cost-effective two-in-one test for influenza and SARS-CoV-2 virus detection in decentralized care environments in low- and middle-income countries (LMIC).

"The collaboration with FIND is very important for Qlife. It enables the development of a completely new test for a specific market with clear needs. We are proud to be part of a development project that can make such a big difference while the development work progresses in accordance with our plan", says Thomas Warthoe, CEO of Qlife.

The financing is paid out in three milestone-based payments, where each payment follows specific R & D performance in the development process. The first payment was made in connection with the signing of the agreement and now the second research-related milestone has now been reached.

This means that Qlife has completed the milestones relating to the analytical verification protocols  which releases a payment of 1.23 M USD. As of date, Qlife has received 2.55 M USD from FIND.

Qlife expects to bring the new influenza/SARS-CoV-2 test capsules to market in select LMICs under a pilot program in 2023.